Telol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telol

What is Telol? Overview

Property Description
Active ingredient Atenolol
Form Tablets (Oral), Solution (Intravenous)
Pharmacological class Beta-blocker (beta1-Selective Adrenergic Antagonist)
General purpose Reduce cardiac workload and blood pressure
Origin Synthetic Compound

Telol: Identity and Pharmacological Classification

Telol is a single-ingredient, prescription-only medication whose active component, Atenolol, is recognized as a beta1-selective adrenergic antagonist, commonly known as a beta-blocker. This classification indicates that the medicine acts by blocking specific receptors in the cardiovascular system. It is supplied primarily as tablets for oral administration, though a preparation for intravenous injection also exists. The specific beta1-selectivity of Atenolol means it concentrates its action predominantly on receptors found in the heart, providing a targeted effect on the main organ responsible for blood circulation.


Composition and Chemical Origin

The active ingredient, Atenolol, is a synthetic organic compound, meaning its precise structure is achieved through specialized chemical synthesis rather than being directly extracted from natural sources. Atenolol possesses relatively low fat solubility (lipophilicity). This characteristic ensures the substance's effects are focused on the peripheral systems. Clinically, this low lipophilicity relates to how the drug is handled by the body, as it is largely eliminated through the kidneys rather than undergoing extensive metabolism in the liver.


General Purpose and Function of a Cardioselective Agent

The primary function of Telol is to reduce strain and promote stability within the cardiovascular system. The medicine works as a sympatholytic agent by blocking the stimulatory effects that stress hormones like adrenaline exert on heart cells. This action results in a reduction of the heart's rate and force of contraction. The overall purpose of using this cardioselective agent is to systematically decrease the cardiac workload to maintain a more stable and efficient circulatory state.

What side effects are possible with Telol?

Possible Side Effects and Safety Information

The safety profile of Telol (Atenolol) is documented by governmental regulatory authorities and outlines known adverse reactions, contraindications, and specific warnings.

Frequency-Classified Adverse Reactions

Side effects are categorized by how often they are expected to occur, based on regulatory data:

Classification Examples of Reactions
Common (1 to 10 users in 100) Bradycardia (slow heart rate), fatigue, cold extremities, gastrointestinal disturbances.
Uncommon Sleep disturbances, elevated liver transaminase levels.
Rare (1 to 10 users in 10,000) Mood changes, nightmares, confusion, dizziness, headache, dry eyes, precipitation of heart block, bronchospasm, hepatic toxicity, impotence, skin rashes.
Very Rare Increase in Antinuclear Antibodies (ANA).
Frequency Not Known Depression, hypersensitivity reactions (angioedema, urticaria), lupus-like syndrome.

Serious Adverse Reactions and System-Organ Classes

The regulatory label identifies several severe risks. These include the deterioration of pre-existing heart failure, the precipitation of heart block, and hepatic toxicity, including intrahepatic cholestasis. Adverse effects are systematically grouped into categories such as Cardiac Disorders, Vascular Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Safety-Related Restrictions (Contraindications and Warnings)

Telol is strictly contraindicated (must not be used) in patients with conditions such as asthma, severe heart block, metabolic acidosis, or hypersensitivity to the drug. Caution is specifically required for patients with diabetes, Prinzmetal's angina, kidney or liver disorders, and poor peripheral circulation. Abrupt discontinuation of the medicine should be avoided, as regulatory documents state this can precipitate severe events like chest pain or heart attack; a gradual dose reduction is necessary.

Population-Specific Safety Considerations

The drug is contraindicated during both pregnancy and breastfeeding. Official documents note that Telol crosses the placenta, with documented risks of foetal growth retardation and death. It also passes into breastmilk and is stated to be potentially fatal for the infant.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented manifestations and required emergency actions for Telol (Atenolol) overdose, strictly according to government regulatory labeling.

Scope Element Official Regulatory Description
Documented Manifestations Symptomatic bradycardia, severe hypotension, acute cardiac failure, bronchospasm, lethargy, and sinus pause.
Systems Affected Cardiovascular, Respiratory, and Metabolic (e.g., hypoglycemia).
Population Notes Increased risk for accumulation in renal impairment. Neonates born to treated mothers are at risk of bradycardia and hypoglycemia.

A Telol overdose is defined by regulatory authorities based on the potential for severe or life-threatening outcomes, including Cardiogenic Shock and a dangerous drop in blood pressure. Urgent medical attention is required for the management of any profound cardiovascular depression or systemic compromise. The official response is strictly symptomatic and supportive treatment. Immediate actions include procedures like gastric lavage or administration of activated charcoal to limit absorption. Due to the lack of a single specific reversal agent, specialized support is detailed, including the use of Intravenous (IV) Glucagon for refractory hypotension or heart failure, and IV Atropine for severe bradycardia. Continuous hospital monitoring is mandated to manage these acute, life-threatening events.

Therapeutic Uses of Telol

Telol is generally used for managing a number of conditions marked by increased physiological stress, and is relevant across domains where additional symptomatic support is needed. Its main therapeutic areas include the management of high blood pressure, certain types of heart-related chest pain, and the management of irregular heart rhythms.


What Telol Treats: Main Uses and Benefits

Telol is commonly used to help manage conditions presenting with acute or disruptive episodes where functional stability becomes affected. This includes scenarios involving symptoms related to systemic imbalance and heightened physiological activity. The goal of symptomatic support is to help maintain a sense of stability when symptoms are more noticeable.

Key Areas of Symptom Management

Telol assists with maintaining functional stability by playing a role in managing symptoms related to systemic imbalance. It is also relevant for easing symptoms related to heart-related chest discomfort and supports patients during episodes of heightened discomfort caused by an irregular heartbeat. It supports general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Heart Discomfort Telol is commonly used to help with symptom clusters that may become intense or disruptive, particularly those related to heart-related distress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Telol is generally allowed for adult use in certain cardiovascular conditions. However, regulatory labeling outlines several populations for whom the medicine is strictly prohibited or restricted.

The medicine is contraindicated and must not be used in patients with severe cardiac issues, including sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. A history of hypersensitivity to the drug's components is also an absolute contraindication, as specified in official documentation.

Eligibility is also defined by physiological status and age. For the pediatric population, safety and efficacy have not been established, and use is generally not recommended. In pregnancy, use is restricted and considered only when the benefit outweighs the potential risk of fetal growth restriction.

Renal impairment requires cautious use, as drug accumulation occurs when kidney function is severely reduced. Caution is also advised in patients with bronchospastic diseases or diabetes, as Telol may mask the symptoms of acute hypoglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Telol (Atenolol) establishes specific interaction patterns based on pharmacodynamic and pharmacokinetic effects with co-administered substances. The profile is primarily defined by additive effects on the cardiovascular system and restrictions based on gastrointestinal absorption.

Drug-Drug and Drug-Substance Interaction Patterns

Co-administration with other negative chronotropic agents, such as Verapamil, Diltiazem, or Digoxin, is officially documented to carry a risk of additive cardiac depression, potentially leading to severe bradycardia (slowed heart rate) or atrioventricular conduction delay. Conversely, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may antagonize the blood pressure-lowering effect of Telol.

Administration timing constraints are mandated for substances that interfere with absorption. Specifically, antacids containing Aluminum Hydroxide and Multivitamins with Minerals must be separated from Telol administration by at least two hours to prevent a reduction in Telol's systemic exposure. The co-administration of alcohol (ethanol) may also contribute to an additive reduction in blood pressure.

While Telol exhibits minimal involvement in the CYP-mediated metabolic pathway, a procedural constraint exists with Clonidine: if both medicines are to be discontinued, Telol must be gradually withdrawn several days before the withdrawal of Clonidine to mitigate the officially documented risk of rebound hypertension.

Population-Specific Interaction Notes

In patients with Diabetes Mellitus, Telol is officially documented to mask the common physiological warning signs of hypoglycemia, a critical pharmacodynamic interaction. Furthermore, in cases of Renal Impairment, Telol's reduced clearance can increase systemic exposure, thereby heightening the potential for interaction severity with other cardiodepressant agents.

Mechanism of Action

How Telol Works: Mechanistic Domains


Selective beta1-Adrenergic Receptor Blockade

Telol functions primarily by antagonizing the beta1-adrenergic receptors, which are highly concentrated in cardiac tissue. This acts within the receptor-mediated signaling domain by competitively binding to the receptor and preventing activation by catecholamines (like norepinephrine and epinephrine). This suppression of sympathetic stimulation initiates the cascade of downstream cardiac effects.


Modulation of Cardiac Rate and Force

The drug modifies early molecular steps that govern heart function by reducing the activity of adenylyl cyclase and its downstream pathways, resulting in negative chronotropic (rate-slowing) and inotropic (force-reducing) effects. This key pathway adjustment contributes to limiting the acceleration of physiological responses, which modifies cardiac function by reducing both chronotropic and inotropic activity.


Regulation of Myocardial Oxygen Demand

The drug influences myocardial oxygen demand by reducing cardiac work. The alteration in heart rate and contractility diminishes the energy and oxygen required by the myocardium, which is relevant in systems where a targeted pathway adjustment is required to modulate physiological activity associated with increased sympathetic drive.

Dosage and Administration Information

How Telol is Used: Established Administration Guidelines

This section describes the instructions for the administration and dosing of Telol.

Entity Detail
Route of Administration Telol is administered via the oral route as tablets or as an intravenous injection for acute, immediate use.
Dosing Schedule and Frequency The oral dosage for maintenance commonly begins at 25 mg to 50 mg once daily, with the typical maintenance range being 50 mg to 100 mg once daily. Doses may be administered once daily, or in divided doses for certain conditions.
Administration Conditions Oral tablets should be swallowed whole with water and can be taken independently of food. Intravenous administration for acute conditions must be performed slowly and initiated under the continuous supervision of a specialized hospital unit.
Dose Adjustments Specific dose modifications are required for individuals with impaired renal function; the maximum daily dose is restricted numerically when creatinine clearance falls below 35 mL/min. A lower starting dose (e.g., 25 mg) is generally advised for older adults, and the medicine is not recommended for the pediatric population.
Procedural Requirements Established protocols require that treatment is not to be stopped abruptly. The dosage must be gradually reduced over a period of 7 to 14 days to conclude therapy. If a routine dose is missed, it should not be doubled, and the schedule should be resumed at the next planned time.

The administration of Telol is defined by these structured instructions, which outline the precise route, frequency, and dose adjustments necessary for standardized use across various patient scenarios, while also dictating the mandatory gradual reduction protocol for therapy conclusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Telol

Research Evidence for Use in High Blood Pressure

The research foundation for Telol in high blood pressure, a condition associated with systemic or functional imbalance, largely stems from Randomized Controlled Trials (RCTs) and meta-analyses that compared it against a dummy treatment (placebo) or non-drug treatment. These studies were designed to measure changes in systolic and diastolic blood pressure over time. Research examined whether changes in blood pressure measurements were observed in the study populations. Some analyses explored whether different patterns in cardiovascular event occurrence were tracked when compared to a non-treatment group. The evidence quality varies across studies, and scientific research continues to further characterize its role within current treatment strategies.


Research Evidence for Use in Stable Heart-Related Chest Pain

Research was studied for exploring outcomes related to chronic stable angina, a condition characterized by fluctuating or episodic manifestations. These trials examined several outcomes related to outcomes related to physical discomfort and daily functioning or activity level. Studies generally reported how symptoms evolved in the observed populations, noting patterns related to slower heart rates and measured shifts in physiological stress markers. Follow-up durations were limited in many of the key studies, meaning long-term effects are not fully established.


Research Evidence Explored Following a Heart Attack

Research was evaluated in large-scale trials, many of which were conducted in the past, tracking outcomes like cardiac mortality and the risk of experiencing a recurrent heart attack. Historic trials described patterns where differences in mortality rates and the occurrence of recurrent heart attacks were tracked between the studied groups and control groups in the pre-reperfusion era. Data for certain groups remain insufficient in the current environment, particularly for long-term study results in patients with preserved heart muscle function.


Areas of Research Uncertainty and Study Gaps

A review of the available research highlights several key areas where the evidence is not fully established. These include limited information for long-term outcomes in some settings and that subgroup findings are uncertain for specific populations, such as those with preserved heart muscle function or those with severe kidney impairment. The results apply only to the populations studied under the specific conditions and standards of the original research.

Key Studies & References

  1. NICE Guideline NG136: Chronic heart failure in adults: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Telol (FAQ)

Q: What is Telol used for, in simple terms?

A: Telol is a prescription medication that functions as a beta-blocker. According to official product information, its general purpose is to reduce the heart’s overall workload and help lower high blood pressure.

Q: How quickly is Telol expected to start working?

A: Regulatory information indicates that the beta-blocking effects of Telol are generally apparent within one hour of oral administration. The maximal effect is usually reached within two to four hours after the dose.

Q: Will Telol cure my condition, or just manage the symptoms?

A: Regulatory information describes Telol as a management therapy. The medication is used to manage long-term conditions. Official documents define its role as supporting cardiac function and lowering blood pressure, rather than providing a cure for the underlying condition.

Q: Is Telol a long-term medication?

A: Telol is generally prescribed for continuous, long-term use in chronic conditions. Regulatory guidelines state that if therapy is to be concluded, the dosage requires gradual reduction over a period of time and should not be stopped abruptly.

Q: Can Telol be taken by older adults?

A: Yes, Telol can be prescribed for older adults. The official prescribing information indicates that a lower starting dose is generally advised for this population.

Q: Does Telol cause weight gain or weight loss?

A: Weight changes are sometimes reported in official adverse reaction listings for Telol. Regulatory documents list weight gain as an uncommon or rare side effect based on post-marketing reports.

Q: Can taking Telol make me feel dizzy or tired?

A: Fatigue is officially listed as a common side effect in regulatory documents. Additionally, dizziness and lightheadedness are reported reactions, and these are often noticed when a person changes position too quickly.

Q: Is Telol known to affect sleep patterns?

A: Official safety data indicates that Telol can affect sleep. Regulatory documents list both general sleep disturbances and nightmares as possible side effects.

Q: Is it necessary to avoid alcohol completely while taking Telol?

A: Regulatory information advises caution regarding alcohol consumption. This is because alcohol may contribute to an additive effect that further reduces blood pressure.

Q: Can I take Telol if I also take a vitamin supplement?

A: Yes, but some timing separation is required. Official guidance states that certain products, such as antacids containing aluminum hydroxide or multivitamins with minerals, must be taken at least two hours apart from Telol to avoid reduced absorption of the medication.

Q: Is Telol available in different strengths or forms?

A: Telol is available in two forms: tablets for oral use and a solution for intravenous injection. The oral tablets are typically supplied in several strengths, such as 25 mg, 50 mg, and 100 mg.

Q: Does Telol need to be taken at a specific time of day?

A: The medication is most often prescribed to be taken once daily. While the official labeling does not mandate a specific time, it is generally taken at a consistent time each day as directed by the prescribing professional.

Q: Are there any ongoing or recent major studies about Telol?

A: The foundational evidence for Telol is based on clinical trials conducted over time. Regulatory documents indicate that scientific research continues in various areas to further define its role within current treatment strategies.

Q: Is Telol described as having a risk of dependence or withdrawal?

A: Regulatory documents contain a serious warning against suddenly stopping Telol. Abrupt discontinuation can worsen heart conditions or lead to a heart attack. This caution relates to the mandated protocol that requires treatment conclusion to be achieved using a gradual dose reduction procedure.

Q: Does Telol have a black box warning or similar strong caution?

A: Yes, the official FDA labeling includes a Boxed Warning. This Boxed Warning addresses the risk of worsening chest pain and the possibility of a heart attack that is associated with abrupt discontinuation of the medication.

Q: Is it true that Telol can sometimes cause a dry mouth?

A: Dry mouth is listed in some regulatory documents. It is described as a rare side effect, meaning it is not expected to affect many users.

Q: What kind of monitoring might be required while taking Telol?

A: Official information indicates that patient progress is typically checked by a healthcare provider at regular intervals while Telol is being used. This monitoring may include blood tests to check for unwanted effects.

Q: Is there any public research on Telol use in people with kidney issues?

A: Regulatory information specifies that dose adjustments are required for individuals with impaired kidney function because the drug is eliminated through the kidneys. Furthermore, some studies indicate uncertainty and data gaps for patients with severe kidney impairment.

Q: What is meant by the 'half-life' of Telol?

A: The half-life is a measure that describes the time required for the amount of drug in the body to be reduced by half. For Telol, the half-life is approximately six to seven hours in people with normal kidney function.

Q: Are there any specific safety precautions mentioned for Telol and driving?

A: Official warnings suggest that caution should be exercised when driving or operating machinery. This precaution is necessary because Telol may cause side effects like dizziness, fatigue, or lightheadedness, which could affect concentration.

Q: Does Telol typically lose its effectiveness over time?

A: Clinical studies have examined the long-term use of Telol. Evidence indicates that the main effects, such as blood pressure reduction and beta-blockade, are generally sustained throughout the 24-hour dosing interval with maintained administration.

Q: What happens to the body when Telol is first started?

A: When first started, Telol begins to block specific receptors in the heart. This action is designed to slow the heart rate and reduce the force of its contraction, thereby decreasing the heart's overall workload.

Q: Is Telol ever used for conditions other than its main approved uses?

A: The official regulatory documents only list the approved indications for Telol. These indications include high blood pressure and specific heart-related conditions.

Q: Does the efficacy of Telol vary between different populations (e.g., genders, ethnic groups)?

A: Regulatory documents indicate that the blood pressure response to this class of medication may differ across various ethnic groups. Furthermore, the available research contains uncertainties for certain other patient subgroups.

Q: Where can I find the full official safety information for Telol?

A: The complete official safety information and prescribing details are published by government drug agencies. These documents are generally available through resources like the FDA's DailyMed database.

Q: How long does the main effect of Telol usually last after taking a dose?

A: The beta1-blocking effects of a standard oral dose are reported in regulatory data to persist for at least 24 hours. This duration supports the once-daily dosing schedule.

Q: Are there different types of Telol preparations (e.g., immediate-release vs. extended-release)?

A: The primary regulatory labels for the single-ingredient product typically describe immediate-release tablets. Extended-release formulations are not commonly described in the core official prescribing information.

Q: What if I'm already taking multiple different medications, can I still take Telol?

A: Many specific drug interactions are documented in the official information, particularly with other heart or blood pressure medications. Official documents describe that all co-administered medicines, including over-the-counter products, should be reviewed by a healthcare provider due to the potential for interactions.

How should Telol be stored and disposed of?

Storage and Environmental Requirements

Telol (atenolol) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from moisture, direct light, and excess heat, and must be kept from freezing.

Packaging and Child Safety

Mandatory regulatory requirements state that the medicine must be kept in its original container and the container must remain tightly closed. For safety, the product must be stored out of the sight and reach of children.

Disposal of Unused Medicine

Unused or expired Telol must be disposed of safely. The preferred method is using a formal drug take-back location or program. If a take-back program is unavailable, official guidance advises mixing the tablets with an unappealing substance (like dirt or coffee grounds) and placing the mixture in a sealed bag before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telol found in:

A-Z Index: